Drug Trial Radar · NCT04675931
To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria
Last checked: Nov 19, 2026Latest source record: Apr 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
254
Actual
Start
Mar 7, 2022
Primary completion
Jul 24, 2025
Study completion Aug 20, 2025
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- Collaborators
- Wellcome Trust; European and Developing Countries Clinical Trials Partnership (EDCTP)
- First posted
- Dec 19, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 6 months, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to identify the safe and effective dose of intravenous cipargamin in participants with moderately severe and severe malaria. The study also intended to evaluate clinical treatment success using a novel clinical endpoint for drug development in severe malaria. Severe malaria is a medical emergency and is affecting primarily young children in Africa. Injectable artesunate is the standard of care for the treatment of severe malaria and is highly efficacious. However, the spread of artemisinin-resistance in Plasmodium falciparum in Asian countries poses a threat for future treatment of patients with this life-threatening disease. To mitigate this risk, there is a need for another drug in malaria-endemic countries. Cipargamin treatment results in rapid clearance of parasites, including artemisinin-resistant parasites.
Conditions
- Severe Malaria
Interventions
CipargaminDrug
Cipargamin, 20 mg or 40 mg, by intravenous administration of solution for injection
IV ArtesunateDrug
Artesunate, 2.4 mg/kg or 3 mg/kg, by intravenous administration of reconstituted solution
CoartemDrug
Oral standard of care (Coartem tablets, dosed per weight, as per label)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving at Least 90% Reduction in Plasmodium Falciparum (P. Falciparum) at 12 HoursTime frame: 12 Hours
Locations
9 sites in 7 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Burkina Faso, Burkina Faso
Novartis Investigative Site
Ouagadougou, Burkina Faso
Novartis Investigative Site
Abidjan, Côte d’Ivoire
Novartis Investigative Site
Agboville, Côte d’Ivoire
Novartis Investigative Site
Kinsasha, Democratic Republic of Congo, Democratic Republic of the Congo
Novartis Investigative Site
Siaya, Kenya
Novartis Investigative Site
Manhiça, Maputo Province, Mozambique
Novartis Investigative Site
Kigali, Rwanda
Novartis Investigative Site
Tororo, Uganda
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.